Dominant negative RAS as an anticancer agent

Cancer Biology and Therapy

Volumn 5, Issue 11, 2006, Pages 1492-1493

  Guo, Wei ^a   Fang, Bingliang ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anticancer; CAAX; Dominant negative; N116Y; Ras

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FARNESYL TRANS TRANSFERASE; GERANYLTRANSFERASE; GROWTH FACTOR RECEPTOR; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATE; RAS PROTEIN;

BLADDER CANCER; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; ESOPHAGUS CANCER; GENE AMPLIFICATION; GENE CONSTRUCT; GENE DELETION; GENE MUTATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NOTE; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; PANCREAS CANCER; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MODIFICATION; SIGNAL TRANSDUCTION; TUMOR CELL; WILD TYPE;

EID: 33846982250     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.11.3681     Document Type: Note

References (18)

1. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, Vogelstein B. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987; 327:293-7.
2. Mills NE, Fishman CL, Rom WN, Dubin N, Jacobson DR. Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res 1995; 55:1444-7.
3. Pellegata NS, Sessa F, Renault B, Bonato M, Leone BE, Solcia E, Ranzani GN. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer ReS 1994; 54:1556-60.
4. Hoa M, Davis SL, Ames SJ, Schrader JW. Amplification of wild-type K-ras promotes growth of head and neck squamous cell carcinoma. Cancer Res 2002; 62:7154-6.
5. Ehrhardt A, David MD, Ehrhardt GR, et al. Distinct mechanisms determine the patterns of differential activation of H-Ras, N-Ras, K-Ras 4B, and M-Ras by receptors for growth factors or antigen. Molecular & Cellular Biology 2004; 24:6311-23.
6. Cox AD, Der CJ. Ras family signaling: therapeutic targeting. Cancer Biol Ther 2002; 1:599-606.
7. Der CJ. The ras family of oncogenes. Cancer Treat Res 1989; 47:73-119.
8. Khosravi-Far R, Der CJ. The Ras signal transduction pathway. Cancer Metastasis Rev 1994; 13:67-89.
9. Wennerberg K, Rossman KL, Der CJ. The Ras superfamily at a glance. J Cell Sci 2005; 118:843-6.
10. Wright LP, Philips MR. Thematic review series: lipid posttranslational modifications. CAAX modification and membrane targeting of Ras. J Lipid Res 2006; 47:883-91.
11. Suzuki H, Kuzumaki S, Nakagawa K Takimoto M, Shichinohe T. Suppressive Effect of Modified Dominant Negative RAS Mutant on Human Cancer by Gene Transfer with Non-Viral Vector. Cancer Biol Ther 2006; 5:In press.
12. Senmaru N, Shichinohe T, Takeuchi M, Miyamoto M, Sazawa A, Ogiso Y, Takahashi T, Okushiba S, Takimoto M, Kato H, Kuzumaki N. Suppression of Erk activation and in vivo growth in esophageal cancer cells by the dominant negative Ras mutant, N116Y. Int J Cancer 1998; 78:366-71.
13. Shichinohe T, Senmaru N, Furuuchi K, Ogiso Y, Ishikura H, Yoshiki T, Takahashi T, Kato H, Kuzumaki N. Suppression of pancreatic cancer by the dominant negative ras mutant, N116Y. J Surg Res 1996; 66:125-30.
14. Takeuchi M, Shichinohe T, Senmaru N, Miyamoto M, Fujita H, Takimoto M, Kondo S, Kato H, Kuzumaki N. The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice. Gene Ther 2000; 7:518-26.
15. Watanabe T, Shinohara N, Sazawa A, Kobayashi Y, Ogiso Y, Kimura T, Takiguchi M, Yasuda J, Hashimoto A, Koyanagi T, Kuzumaki N. Suppressive effects of dominant negative ras mutant N116Y on transformed phenotypes of human bladder cancer cells. Cancer Lett 2000; 149:195-202.
16. Watanabe T, Shinohara N, Sazawa A, Takimoto M, Hashimoto A, Koyanagi T, Kuzumaki N. Adenovirus-mediated gene therapy for bladder cancer in an orthotopic model using a dominant negative H-ras mutant. Int J Cancer 2001; 92:712-7.
17. Stacey DW, Feig LA, Gibbs JB. Dominant inhibitory Ras mutants selectively inhibit the activity of either cellular or oncogenic Ras. Mol Cell Biol 1991; 11:4053-64.
18. Stewart S, Guan KL. The dominant negative Ras mutant, N17Ras, can inhibit signaling independently of blocking Ras activation. J Biol Chem 2000; 275:8854-62.